We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance
Read MoreHide Full Article
Alkermes plc. (ALKS - Free Report) reported adjusted earnings of 26 cents per share in the third quarter of 2020 against a loss of 4 cents reported in the year-ago quarter. The Zacks Consensus Estimate was pegged at a loss of a cent.
The company’s revenues of $265 million in the quarter increased 3.8% from the year-ago quarter. The top-line beat the Zacks Consensus Estimate of $239 million.
Alkermes’ shares have lost 20.2% so far this year compared with the industry’s decline of 6.4%.
Quarter Details
Total manufacturing and royalty revenues were up 16% year over year to $120.4 million. Manufacturing and royalty revenues from J&J’s (JNJ - Free Report) drugs — Risperdal Consta, Invega Sustenna/Xeplion and Invega Trinza/Trevicta — were $87.9 million, up 14.6% year over year.
Vivitrol sales decreased about 6% year over year to $80.3 million. The decline resulted mainly due to COVID-19-related disruptions.
Aristada sales came in at $62.4 million, up 16% year over year, driven primarily by the increased breadth of the Aristada provider base and growth in the drug’s two-month dose.
Research and development (R&D) expenses were $95 million, down 11.8% year over year.
Selling, general and administrative (SG&A) expenses were $127.7 million, down 16.4% year over year.
Pipeline Updates
In October 2020, the company received positive vote outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee appointed by the FDA, on questions relating to ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder. The joint advisory committee's recommendations, while not binding, will be considered by the FDA in its review of the ALKS 3831 new drug application (NDA). The action date for the NDA is Nov 15, 2020.
In August 2020, the company announced the initiation of ARTISTRY-3, a phase II study evaluating the clinical and immunologic effects of ALKS 4230 monotherapy administered intravenously on the tumor microenvironment in a variety of advanced, malignant solid tumors.
2020 GuidanceRaised
The company now expects total revenues of,$1,010-$1,035 million,up from the previous expectation of $965-$1,005 million. It expects Vivitrol net sales of $305-$315 million, up from the prior expectations of $270-$300 million. Aristada net sales are expected to be $230-$240 million, up from the previous expectation of $220-$235 million
Earnings are expected between 31-43 cents per share,up from, the earlier expectation of break-even and 19 cents per share.
Zacks Rank and Stocks to Consider
Currently, Alkermes is a Zacks Rank #3 (Hold) stock.
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Image: Bigstock
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance
Alkermes plc. (ALKS - Free Report) reported adjusted earnings of 26 cents per share in the third quarter of 2020 against a loss of 4 cents reported in the year-ago quarter. The Zacks Consensus Estimate was pegged at a loss of a cent.
The company’s revenues of $265 million in the quarter increased 3.8% from the year-ago quarter. The top-line beat the Zacks Consensus Estimate of $239 million.
Alkermes’ shares have lost 20.2% so far this year compared with the industry’s decline of 6.4%.
Quarter Details
Total manufacturing and royalty revenues were up 16% year over year to $120.4 million. Manufacturing and royalty revenues from J&J’s (JNJ - Free Report) drugs — Risperdal Consta, Invega Sustenna/Xeplion and Invega Trinza/Trevicta — were $87.9 million, up 14.6% year over year.
Vivitrol sales decreased about 6% year over year to $80.3 million. The decline resulted mainly due to COVID-19-related disruptions.
Aristada sales came in at $62.4 million, up 16% year over year, driven primarily by the increased breadth of the Aristada provider base and growth in the drug’s two-month dose.
Research and development (R&D) expenses were $95 million, down 11.8% year over year.
Selling, general and administrative (SG&A) expenses were $127.7 million, down 16.4% year over year.
Pipeline Updates
In October 2020, the company received positive vote outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee appointed by the FDA, on questions relating to ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder. The joint advisory committee's recommendations, while not binding, will be considered by the FDA in its review of the ALKS 3831 new drug application (NDA). The action date for the NDA is Nov 15, 2020.
In August 2020, the company announced the initiation of ARTISTRY-3, a phase II study evaluating the clinical and immunologic effects of ALKS 4230 monotherapy administered intravenously on the tumor microenvironment in a variety of advanced, malignant solid tumors.
2020 Guidance Raised
The company now expects total revenues of,$1,010-$1,035 million,up from the previous expectation of $965-$1,005 million. It expects Vivitrol net sales of $305-$315 million, up from the prior expectations of $270-$300 million. Aristada net sales are expected to be $230-$240 million, up from the previous expectation of $220-$235 million
Earnings are expected between 31-43 cents per share,up from, the earlier expectation of break-even and 19 cents per share.
Zacks Rank and Stocks to Consider
Currently, Alkermes is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Emergent BioSolutions Inc. (EBS - Free Report) , and Vericel Corp. (VCEL - Free Report) , both carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $5.31 to $6.61 for 2020 and from $6.06 to $8.42 for 2021 in the past 90 days.
Vericel’s loss per share estimates have narrowed from 13 cents to 12 cents for 2020 in the past 60 days.
Alkermes plc Price, Consensus and EPS Surprise
Alkermes plc price-consensus-eps-surprise-chart | Alkermes plc Quote
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Check out Zacks’ 2020 Election Stock Report >>